Urol. praxi, 2016; 17(1): 7-10 | DOI: 10.36290/uro.2016.002

PET/CT scanning in patients with prostate cancer

MUDr.Václav Ptáčník, MUDr.Jozef Kubinyi, Ph.D.
Ústav nukleární medicíny 1. LF UK a VFN v Praze

Prostate cancer (PC) is one of the most common malignant tumours in men. Screening for prostate cancer, including its recurrence or metastases, using conventional imaging techniques is usually relatively poorly sensitive. Fluorodeoxyglucose, the most widely used radiopharmaceutical for positron emission tomography (PET), also exhibits low sensitivity for detecting prostate cancer. Fluorine- labelled choline (FCH) that is especially sensitive in detecting bone and soft-tissue metastases of prostate cancer is currently available in the Czech Republic and is thus becoming a major diagnostic tool, particularly in evaluating the relapse of prostate cancer.

Keywords: PET, CT, prostate cancer, 18F-fluoromethylcholine

Published: February 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ptáčník V, Kubinyi J. PET/CT scanning in patients with prostate cancer. Urol. praxi. 2016;17(1):7-10. doi: 10.36290/uro.2016.002.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ústav zdravotnických informací a statistiky ČR, Národní onkologický registr ČR; Novotvary 2010 ČR, ISBN: 978-80-7472-034-5.
    2. Mottet J, Bellmunt E, Briers RCN, van den Bergh, Bolla M, van Casteren NJ, Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, van der Poel H, van der Kwast TH, Rouvi?re OT. Wiegel Guidelines on Prostate Cancer. Dostupné z: http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf
    3. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging Prostate Cancer: A Multidisciplinary Perspective. Radiology. April 2007; 243(1): 28-53. Go to original source... Go to PubMed...
    4. Van den Bergh L, Lerut E, Haustermans K, Deroose CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM, Bogaerts K, Van Poppel H, Joniau S. Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urologic Oncology 2015; 33(3): 109.e23-31. Go to original source... Go to PubMed...
    5. Pinaquy JB, De Clermont-Galleran H, Pasticier G, Rigou G, Alberti N, Hindie E, Mokrane Y, Fernandez P. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. The Prostate. 2015; 75(3): 323-331. Go to original source... Go to PubMed...
    6. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F, Machiels JP, Vande Berg B, Omoumi P, Tombal B. Can Whole-body Magnetic Resonance Imaging with Diffusion-weighted Imaging Replace Tc 99m Bone Scanning and Computed Tomography for Single-step Detection of Metastases in Patients with High-risk Prostate Cancer? European Urology 62. 2012; Volume 62(1): 68-75. Go to original source... Go to PubMed...
    7. Hövels AM, Heesakkers RA, Adang EM, Jager GJ, Strum S, Hoogeveen YL, Severens JL, Barentsz JO. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clinical Radiology 2008; 63(4): 387-395. Go to original source... Go to PubMed...
    8. Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology. 2006; 67(4): 769-773. Go to original source... Go to PubMed...
    9. Rosser CJ, Chichakli R, Levy LB, Kuban DA, Smith LG, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostatecancer treated with external-beam radiation. J Urol Aug 2002; 168(2): 536-541. Go to original source... Go to PubMed...
    10. Cirillo S, Petracchini M, Scotti L, Gallo T, Macera A, Bona MC, Ortega C, Gabriele P, Regge D. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol. Mar 2009; 19(3): 761-769. Go to original source... Go to PubMed...
    11. Cher ML, Bianco FJ Jr, Lam JS, Davis LP, Grignon DJ, Sakr WA, Banerjee M, Pontes JE, Wood DP Jr. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol Oct 1998; 160(4): 1387-1391. Go to original source... Go to PubMed...
    12. Kane CJ, Amling CL, Johnstone PA, Pak N, Lance RS, Thrasher JB, Foley JP, Riffenburgh RH, Moul JW. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology Mar 2003; 61(3): 607-611. Go to original source... Go to PubMed...
    13. Helyar V, Mohan HK, Barwick T, Livieratos L, Gnanasegaran G, Clarke SE, Fogelman I. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. European Journal of Nuclear Medicine and Molecular Imaging. 2010; 37(4): 706-713. Go to original source... Go to PubMed...
    14. Bauman G, Belhocine T, Kovacs M, Ward A, Beheshti M, Rachinsky I. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012; 15(1): 45-55. Go to original source... Go to PubMed...
    15. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, Martínez-Pi?eiro L, Sánchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002; 296(3): 580-583. Go to original source... Go to PubMed...
    16. Murray RK, Granner DK, Mayes PA, Rodwell VW. Harperova biochemie. 23. (3. české). Jinočany: Nakladatelství a vydavatelství H&H, 2001; 153: 254. ISBN 80-7319-003-6.
    17. Beauregard JM, Williams SG, Degrado TR, Roselt P, Hicks RJ. Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer. J Med Imaging Radiat Oncol. 2010; 54(4): 325-332. Go to original source... Go to PubMed...
    18. Cimitan M, Bortolus R, Morassut S, Canzonieri V, Garbeglio A, Baresic T, Borsatti E, Drigo A, Trov? MG. [18F] fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006; 33(12): 1387-1398. Go to original source... Go to PubMed...
    19. Pelosi Pelosi E, Arena V, Skanjeti A, Pirro V, Douroukas A, Pupi A, Mancini M. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008; 113(6): 895-904. Go to original source... Go to PubMed...
    20. Sandi A, Kwee, MD, Hai Wei, Isabell Sesterhenn, David Yun, Marc N. Coel. Localization of Primary Prostate Cancer with Dual-Phase 18F-Fluorocholine PET. J Nucl Med. 2006; 47(2): 262-269. Go to PubMed...
    21. Beheshti M, Imamovic L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254: 925-933. Go to original source... Go to PubMed...
    22. Igerc I, Kohlfürst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P. The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2008; 35(5): 976-983. Go to original source... Go to PubMed...
    23. Beheshti M, Vali R, Waldenberger P, Fitz F, Nader M, Hammer J, Loidl W, Pirich C, Fogelman I, Langsteger W. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imag Biol 2009; 11(6): 446-454. Go to original source... Go to PubMed...
    24. Wondergem M, van der Zant FM, van der Ploeg T, Knol RJ. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer. Nuclear Medicine Commun. 2013; 34(10): 935-945. Go to original source... Go to PubMed...
    25. Shen G, Deng H, Hu S, Jia Z. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43(11): 1503-1513. Go to original source... Go to PubMed...
    26. Poulsen MH, Petersen H, H?ilund-Carlsen PF, Jakobsen JS, Gerke O, Karstoft J, Steffansen SI, Walter S. Spine metastases in prostate cancer: comparisonof technetium-99m-MDP whole-body bonescintigraphy, [18F]choline positron emissiontomography(PET)/computed tomography (CT)and [18F]NaF PET/CT. BJU International 2014; 114(6): 818-823. Go to original source... Go to PubMed...
    27. Kitajima K, Murphy RC, Nathan MA, Froemming AT, Hagen CE, Takahashi N, Kawashima A. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J Nucl Med. 2014; 55(2): 223-232. Go to original source... Go to PubMed...
    28. Brogsitter C, Zöphel K, Kotzerke J. 18F-Choline, 11C-choline and 11C-acetate PET/CT: comparative analysis for imaging prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2013; 40(Suppl 1): S18-27. Go to original source... Go to PubMed...
    29. Castellucci P, Jadvar H. PET/CT in prostate cancer: non-choline radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2012; 56(4): 367-374. Go to PubMed...
    30. Jadvar H Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013; 40(Suppl 1): S5-10.
    31. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Kübler H, Haberkorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M Evaluation of hybrid 68Ga-PSMA-ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015 Mar 19. pii: jnumed.115.154153 [Epub ahead of print]. Go to original source... Go to PubMed...
    32. Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, Bander NH, Goldsmith SJ Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTA-huJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm. 2015 Mar 13. [Epub ahead of print]. Go to original source... Go to PubMed...
    33. Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, Joyal J, Kopka K, Debus J, Babich JW, Haberkorn U. Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014; 41(7): 1280-1292. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.